February 23, 2017
Novocure Announces Departure of Chief Commercial Officer
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that its Chief Commercial Officer, Peter Melnyk, will be leaving the company to pursue other interests. Mr. Melnyk will continue his employment with the company until March 15, 2017 to ensure a smooth transition. “I want to thank… Read More
learn more
February 23, 2017
Novocure Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Company Update
Continued growth in active patients with 1,091 active patients at December 31, 2016, an increase of 80 percent from December 31, 2015, and 11 percent from September 30, 2016 Fourth quarter 2016 net revenues of $30.2 million, reflecting 144 percent growth versus fourth quarter 2015 and 40… Read More
learn more
February 15, 2017
First Patient Enrolled in Novocure’s Phase 3 Pivotal LUNAR Trial Testing Tumor Treating Fields for the Treatment of Advanced Non-Small Cell Lung Cancer After Failing Platinum-Based Therapy
The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled… Read More
learn more
February 7, 2017
Novocure to Participate in the BIO 2017 CEO & Investor Conference
ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in the BIO 2017 CEO & Investor Conference on Feb. 13, 2017, in New York City. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s… Read More
learn more
